SBA Member, 24.10.2018
Polyphor announces protocol agreement with the FDA for the second pivotal Phase III study of murepavadin
Polyphor has started PRISM-UDR Phase III clinical trial of the pathogen-specific antibiotic murepavadin in patients with nosocomial pneumonia and expects to begin recruitment by Q119.
Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including overall survival
Polyphor presented new efficacy data on its immuno-oncology candidate, balixafortide, at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the transition
Chief Medical and Development Officer Debra Barker has decided to leave Polyphor at year end for personal reasons and will support on a part time basis afterwards. Frank Weber, member of the Board, will further support the company during the transition and assume ad interim the CMDO responsibility from January 1st, 2019. A search for a replacement has been launched.